Low-Dose Thrombolysis Plus Argatroban Signals Benefit in Ischemic Stroke
A retrospective cohort links adjunctive argatroban after reduced-dose thrombolysis to better early neurological recovery without excess bleeding, but the nonrandomized design confines the findings to hypothesis-generating status.
Combining tenecteplase with argatroban might enhance stroke recovery.
Intravenous thrombolysis is crucial for acute ischemic stroke management, but optimizing reperfusion while minimizing rethrombosis is challenging. Adding argatroban to low-dose tenecteplase improved early neurological outcomes and functional recovery without significantly increasing adverse events. These findings from a single-center, retrospective study are promising but require further validation through randomized controlled trials to confirm efficacy and safety. Tenecteplase plus argatroban shows potential for better outcomes in acute ischemic stroke patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Huang S, Wang X, Li D, et al. Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study. Medicine. 2026;105(29):e49809. doi:10.1097/MD.0000000000049809
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.